Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

Affiliations

• ¹ Universitaire Ziekenhuizen Leuven, Belgium.
• ² Cliniques Universitaires Saint-Luc, Brussels, Belgium.
• ³ Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
• ⁴ Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
• ⁵ Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.
• ⁶ Heilig Hartziekenhuis, Lier, Belgium.
• ⁷ AZ Nikolaas, Haematology, Sint-Niklaas, Belgium.
• ⁸ Janssen-Cilag NV, Beerse, Belgium.
• ⁹ Realidad bvba, Grimbergen, Belgium.
• ¹⁰ Janssen Pharmaceutica NV, Beerse, Belgium.
• ¹¹ Janssen-Cilag SpA, Cologno Monzese, Italy.
• ¹² Cilag GmbH International, Zug, Switzerland.
• ¹³ Janssen-Cilag BV, Breda, the Netherlands.
• ¹⁴ Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium.